ArticleEFSA journal. European Food Safety Authority2025
Impact of the use of azole fungicides, other than as human medicines, on the development of azole-resistant
Article in EFSA journal. European Food Safety Authority, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Decreased DMI sensitivity of Plenodomus biglobosus (phoma of oilseed rape) associated with CYP51 substitution G476S.Pest management science · 2026Article
- Early Cellular Responses ofAntibiotics (Basel, Switzerland) · 2026Article
- Amino acid substitutions at the G118 hotspot in dihydroorotate dehydrogenase confer olorofim resistance inMicrobiology spectrum · 2026Article
- WHO Critical- and High-Priority Fungal Pathogens Beyond Human Medicine: Expanding One Health Surveillance.Pathogens (Basel, Switzerland) · 2026Article
- Addressing the dual-use of antifungals and fungal antimicrobial resistance (fAMR) through a One Health approach.npj antimicrobials and resistance · 2026Review
- A combined approach using environmental yeasts and microbial indicators to assess aquatic pollution.Environmental monitoring and assessment · 2026Article
- Nano-enabled Control of A. flavus and F. proliferatum: inhibition of fungal growth and mycotoxin biosynthesis by zinc oxide nanoparticles.Scientific reports · 2026Article
- Article
- The dual role of azoles: lifesaving antifungals and drivers of resistance - a One Health perspective.Nature communications · 2026Review
- Non-Journal of clinical microbiology · 2026Observational
- Machine learning identifies novel signatures of antifungal drug resistance in Saccharomycotina yeasts.PLoS genetics · 2026Article
- Global epidemiology of azole resistance inJAC-antimicrobial resistance · 2026Review
- A One Health Perspective onJournal of fungi (Basel, Switzerland) · 2026Article
- Predicted no effect concentrations of antifungals for wastewater management and agricultural use.Frontiers in toxicology · 2026Review
- Structural barriers to antifungal drug development.Frontiers in cellular and infection microbiology · 2026Review
- Sexual reproduction and the polygenic architecture of azole resistance in agricultural populations ofFrontiers in microbiology · 2026Article
- Article
- Pathogenesis and Triazole Resistance inInfection and drug resistance · 2026Review
- Invasive Pulmonary Aspergillosis in Non-Neutropenic Patients: An Evolving Clinical Paradigm.Diagnostics (Basel, Switzerland) · 2025Review
- Drug Discovery and Repurposing forJournal of fungi (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of azoles in the European Union and European Economic Area (EU/EEA) other than as human medicines has raised concerns about emergence and spread of azole-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.